Genome-wide target profiling of piggyBac and Tol2 in HEK 293: pros and cons for gene discovery and gene therapy by Meir, Yaa-Jyuhn J et al.
RESEARCH ARTICLE Open Access
Genome-wide target profiling of piggyBac and
Tol2 in HEK 293: pros and cons for gene
discovery and gene therapy
Yaa-Jyuhn J Meir
1*, Matthew T Weirauch
2, Herng-Shing Yang
3, Pei-Cheng Chung
4,R o b e r tKY u
5 and Sareina C-Y Wu
4*
Abstract
Background: DNA transposons have emerged as indispensible tools for manipulating vertebrate genomes with
applications ranging from insertional mutagenesis and transgenesis to gene therapy. To fully explore the potential
of two highly active DNA transposons, piggyBac and Tol2, as mammalian genetic tools, we have conducted a side-
by-side comparison of the two transposon systems in the same setting to evaluate their advantages and
disadvantages for use in gene therapy and gene discovery.
Results: We have observed that (1) the Tol2 transposase (but not piggyBac) is highly sensitive to molecular
engineering; (2) the piggyBac donor with only the 40 bp 3’-and 67 bp 5’-terminal repeat domain is sufficient for
effective transposition; and (3) a small amount of piggyBac transposases results in robust transposition suggesting
the piggyBac transpospase is highly active. Performing genome-wide target profiling on data sets obtained by
retrieving chromosomal targeting sequences from individual clones, we have identified several piggyBac and Tol2
hotspots and observed that (4) piggyBac and Tol2 display a clear difference in targeting preferences in the human
genome. Finally, we have observed that (5) only sites with a particular sequence context can be targeted by either
piggyBac or Tol2.
Conclusions: The non-overlapping targeting preference of piggyBac and Tol2 makes them complementary
research tools for manipulating mammalian genomes. PiggyBac is the most promising transposon-based vector
system for achieving site-specific targeting of therapeutic genes due to the flexibility of its transposase for being
molecularly engineered. Insights from this study will provide a basis for engineering piggyBac transposases to
achieve site-specific therapeutic gene targeting.
Background
DNA transposons are natural genetic elements residing
in the genome as repetitive sequences. A simple trans-
poson is organized by terminal repeat domains (TRDs)
embracing a gene encoding a catalytic protein, transpo-
sase, required for its relocation in the genome through a
“cut-and-paste” mechanism. Since the first discovery of
DNA transposons in Maize by Barbara#McClintock in
1950 [1], transposons have been used extensively as
genetic tools in invertebrates and in plants for
transgenesis and insertional mutagenesis [2-7]. Such
tools, however, have not been available for genome
manipulations in vertebrates or mammals until the reac-
tivation of a Tc1/mariner-like element, Sleeping Beauty,
from fossils in the salmonid fish genome [8]. Since its
awakening, Sleeping Beauty has been used as a tool for
versatile genetic applications ranging from transgenesis
to functional genomics and gene therapy in vertebrates
including fish, frogs, mice, rats and humans [9]. Subse-
quently, naturally existing transposons, such as Tol2 and
piggyBac, have also been shown to effectively transpose
in vertebrates.
The Medaka fish (Orizyas latipes) Tol2,b e l o n g i n gt o
the hAT family of transposons, is the first known natu-
rally occurring active DNA transposon discovered in
vertebrate genomes [10]. Tol2 is a standard tool for
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strated to transpose effectively in frog, chicken, mouse
and human cells as well [11]. Recent studies found that
Tol2 is an effective tool both for transgenesis via pro-
nuclear microinjection and germline insertional muta-
genesis in mice [12]. Cabbage looper moth (Trichoplusia
ni) piggyBac is the founder of the piggyBac superfamily
and is widely used for mutagenesis and transgenesis in
insects [13]. Recently, piggyBac was shown to be highly
active in mouse and human cells and has emerged as a
promising vector system for chromosomal integration,
including insertional mutagenesis in mice and nuclear
reprogramming of mouse fibroblasts to induced-pluripo-
tent stem cells [14-19].
To date, most gene therapy trials have utilized viral
vectors for permanent gene transfer due to their high
transduction rate and their ability to integrate therapeu-
tic genes into host genomes for stable expression. How-
ever, serious problems associated with most viral
vectors, such as limited cargo capacity, host immune
response, and oncogenic insertions (as evidenced by the
retrovirus-based gene therapy) highlight an urgent need
for developing effective non-viral therapeutic gene deliv-
ery systems [20,21]. Recently, Sleeping Beauty, Tol2, and
piggyBac transposon-based vector systems have been
explored for their potential use in gene therapy with
proven successes [22-25]. However, for therapeutic pur-
poses, a large cargo capacity is often required. The
transposition efficiency of Sleeping Beauty is reduced in
a size-dependent manner with 50% reduction in its
activity when the size of the transposon reaches 6 kb
[26]. Tol2 and piggyBac, however, are able to integrate
up to 10 and 9.1 kb of foreign DNA into the host gen-
ome, respectively, without a significant reduction in
their transposition activity [14,22]. Additionally, by a
direct comparison, we have observed that Tol2 and pig-
gyBac are highly active in all mammalian cell types
tested, unlike SB11 (a hyperactive Sleeping Beauty),
which exhibits a moderate and tissue-dependent activity
[15]. Because of their high cargo capacity and high
transposition activity in a broad range of vertebrate cell
types, piggyBac and Tol2 are two promising tools for
basic genetic studies and preclinical experimentation.
Our goal here was to evaluate the pros and cons of pig-
gyBac and Tol2 for the use in gene therapy and gene
discovery by performing a side-by-side comparison of
both transposon systems. In this study, we reported for
the first time the identification of the shortest effective
piggyBac TRDs as well as several piggyBac and Tol2 hot-
spots. We also observed that piggyBac and Tol2 display
non-overlapping targeting preferences, which makes
them complementary research tools for manipulating
mammalian genomes. Furthermore, piggyBac appears to
be the most promising vector system for achieving
specific targeting of therapeutic genes due to a robust
enzymatic activity of the piggyBac transposase and flex-
ibility the transposase displays towards molecular engi-
neering. Finally, results of our in-depth analyses of
piggyBac target sequences highlight the need to first
scrutinize the piggyBac favored target sites for the thera-
peutic cell type of interest before designing a custo-
mized DNA binding protein for fusing with the
piggyBac transposase to achieve site-specific therapeutic
gene targeting.
Results
Transposition activity of piggyBac and Tol2 in mammalian
cells
With the ultimate goal of identifying and targeting safe
sites in the genome at which to insert corrective genes,
we previously explored three active mammalian transpo-
sases, piggyBac, Tol2 and SB11 (a hyperactive Sleeping
Beauty) for their sensitivity to molecular modification
[15]. After fusing the GAL4 DNA binding domain to
the N-terminus of the three transposases, we only
detected a slight change in the activity of the piggyBac
transposase, whereas the same modification nearly abol-
ished the activity of Tol2 and SB11 [15]. A recent
genetic screen has yielded a novel hyperactive Sleeping
Beauty transposase (designated as SB100X) that was
shown to be more active than piggyBac under restrictive
conditions that support their peak activity [28]. How-
ever, in this study we chose to focus on piggyBac and
Tol2 but not Sleeping Beauty for the following reasons:
(1) all of the reported attempts to modify the SB11
transposase either N- or C-terminally result in a com-
plete elimination or a significant reduction in transpo-
sase activity; (2) Sleeping Beauty is more susceptible to
over expression inhibition than piggyBac and Tol2;( 3 )
the cargo capacity of Sleeping Beauty is limited; and (4)
unlike Tol2 and piggyBac that are active in all mamma-
lian cell types tested, Sleeping Beauty display cell-type
dependent activity [15,27,34].
We have demonstrated that piggyBac and Tol2 display
high transposition activity in several cell lines [15]. We
now wish to explore the possibility of further enhancing
their activity by trimming non-essential sequences from
both transposons. Using a PCR-based strategy we gener-
ated pPB-cassette3short with the shortest TRDs
reported replacing the long ones of the pXLBacII-cas-
sette (Figure 1A) [29,30]. Similarly, based on the pre-
vious report, a new Tol2 donor, pTol2mini-cassette,
with minimal terminal repeats [31] replacing the long
ones of Tol2ends-cassette was also constructed (Figure
1A). The new helper plasmids of piggyBac (pPRIG-piggy-
Bac)a n dTol2 (pPRIG-Tol2) were also constructed by
placing cDNA of piggyBac and Tol2 transposases,
respectively, in the bi-cistronic transcriptional unit with
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Page 2 of 19GFP driven by the CMV promoter in the pPRIG vector
(a gift kindly provided by Dr. Patrick Martin) (Figure
1A). To compare the transposition activity of the long
versus short version of piggyBac and Tol2,t h epiggyBac
or Tol2 d o n o rw i t he i t h e rl o n go rs h o r tT R D sw a sc o -
transfected with its helper plasmid into HEK 293 cells.
The transfected cells were subjected to a chromosomal
transposition assay (as detailed in reference 32) to deter-
mine their transposition activity. Removing the majority
of the terminal repeat sequences of piggyBac and Tol2
resulted in a 2.6- and 4.7-fold increase in transposition
activity as compared to their wild-type counterparts
(Figure 1B). Given that the sizes of the piggyBac and
Tol2 donor plasmids are reduced by 1.75-and 1.4- fold,
respectively, the observed increases in transposition
activity for piggyBac and Tol2 are in effect 1.5- and 3.3-
fold when normalized by the number of donor mole-
cules transfected. True transpositions of pPB-cassette3-
short and pTol2mini-cassette in HEK 293 were further
confirmed by retrieving chromosomal sequences flank-
ing their target site (data not shown).
In order to further explore their potential to be modi-
fied by molecular engineering, we Myc tagged the N-ter-
minus of the piggyBac transposase (Myc-piggyBac)a n d
HA tagged both the N- or C-terminus of the Tol2 trans-
posase (HA-Tol2 and Tol2- H A )( F i g u r e2 A ) .B yc o -
transfecting pPB-cassette3short, and the helper plasmid
expressing either wild-type or the chimeric piggyBac
transposase into HEK 293 cells, we observed a slight
increase in activity with the Myc-piggyBac as compared
to its wild type counterpart (Figure 2B). An increase in
activity after molecular modifications was also observed
in several of our piggyBac chimeras including the
GAL4-piggyBac which displayed a fluctuated activity
that was sometimes higher than the wild-type piggyBac
transposase (15 and Meir et. al., unpublished observa-
tions). Similar approaches, however, demonstrated that
fusing the HA tag to either end of the Tol2 transposase
almost completely eliminated its activity (Figure 2B).
To evaluate the activity of the piggyBac transposase,
we then transfected a fixed amount of piggyBac donors
(100 ng) with a various amount of helper plasmids bear-
ing Myc-tagged piggyBac transposases (ranging from 50
to 300 ng) into HEK 293. PiggyBac transposition activity
increases as the amount of piggyBac transposases
increase until reaching its peak in cells transfected with
200 ng of helper plasmids (Figure 2C). As the amount
of piggyBac transposases were reduced to the level
Figure 1 Comparison of transposition activity between the long and short versions of piggyBac and Tol2. A. Donor and helper constructs
of piggyBac and Tol2 used for the comparison. The activator sequence with enhancer activity in D. melanogaster is underlined. B. Transposition
activity of the long vs. short version of piggyBac and Tol2 in HEK 293.
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Page 3 of 19Figure 2 Transposition activity of various engineered Tol2 and piggyBac transposases. A. A schematic representation of tagged piggyBac
and Tol2 transposases. B. The activity comparison between the wild-type and various epitope-tagged Tol2 and piggyBac transposases. C. The
enzymatic activity of Myc-piggyBac. The enzymatic activity of Myc-piggyBac was measured under a fixed amount of pB-cassette3short (donor at
100 ng) co-transfected with increasing amounts of pCMV-Myc-piggyBac helpers (expressing the Myc-tagged piggyBac transposase) into HEK 293
cells. The lower panel depicts a Western blot indicating the expression level of the piggyBac transposase (detected by Myc antibody) and a-actin
(detected by a-actin antibody) in the corresponding transfected cells. Western blotting was performed by isolating protein extracts from the
remaining transfected cells of the same triplicate samples for the colony formation assay shown above.
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Page 4 of 19barely detected by Western blotting, 68% of the transpo-
sition activity at its peak was still retained (compare lane
5 with lane 2 in Figure 2C), suggesting that piggyBac
transposase is highly active.
A global evaluation of Tol2 and piggyBac targeting
preferences in the human genome
Genome-wide target profiling of piggyBac and Tol2 in
the human genome has been reported recently [33-36].
However, all these studies were based on data sets
obtained by retrieving chromosomal targeting sequences
from a mixed population of transposon targeted cells or
using a PCR-based strategy. To fully explore their
potential as mammalian genome manipulation tools for
gene therapy and gene discovery, reliable data sets of
target sequence preferences based on targeting
sequences retrieved form independent integrants are
needed for genome-wide target profiling of piggyBac and
Tol2 in the human genome. In this regard, as for piggy-
Bac, we co-transfected pXLBacII-cassette and pPRIG-
piggyBac into HEK 293 cells. Likewise, Tol2ends-cassette
and pPRIG-Tol2 were co-transfected into HEK 293 for
Tol2. The transfected cells were subjected to colony for-
mation under hygromycin selection at a low density
enabling for isolating individual colonies without cross-
contamination (see Methods for details). Hygromycin-
resistant colonies for piggyBac and Tol2 were individu-
ally cloned and further expanded. Genomic DNA iso-
lated from individual clones was subjected to plasmid
rescue for obtaining chromosomal DNA flanking the
transposon insertion sites. We have isolated 164 and
114 individual colonies for Tol2 and piggyBac, respec-
tively (Table 1). A total of 371 and 264 independent
plasmids were respectively rescued from 142 Tol2 and
104 piggyBac colonies (Table 1) and subsequently
sequenced. Only 149 and 315 of piggyBac and Tol2 tar-
gets resulted in a sequence of sufficient quality to exe-
cute a Blat search against the human genome database
in the UCSC Genome Browser [37]. Among these, 107
piggyBac and 207 Tol2 targeting sequences had a strong
match (over 95% sequence identity) to human genomic
sequences (Table 1).
Based on the established data sets (Table 1), we per-
formed target profiling of piggyBac and Tol2 in the HEK
293 genome. Tol2 and piggyBac display non-overlapping
targeting profiles, with targets scattered over the entire
genome (Figure 3). Although Tol2 targets were detected
in all 23 human chromosomes (HEK 293 lacks the Y
chromosome due to its female origin), no piggyBac tar-
gets were found in chromosome 15 (Figure 3). Interest-
ingly, clusters of Tol2 targets within a 10 kb interval are
often detected (four clusters as circled in purple in Fig-
ure 3 and supplementary 1), whereas no such clusters
are apparent for piggyBac. Tol2 predominately targets
intergenic regions (61.1%), whereas more than half of
the piggyBac targets are located within known genes
(51.6%) (Figure 4A). With respect to intragenic targeting
preferences, both piggyBac and Tol2 favorably target the
introns of known genes and no piggyBac target is found
within the ORF of a gene. Regarding the target distribu-
tion in the UTR region, piggyBac displays a skew
towards the 3’ UTR, while no such bias can be seen in
Tol2 (Figure 4A). Finally, consistent with previous
reports [33-35], both piggyBac and Tol2 h a v eas i g n i f i -
cant bias for integrating close to CpG islands, as com-
pared to the computer simulated random integrations,
with a higher bias detected in piggyBac than in Tol2
(Figure 4A).
To measure the distributions of piggyBac and Tol2 tar-
gets with regards to the gene density around the target
sites, we counted the number of genes located within a
200 kb interval on either side of their target sites. By
this analysis, Tol2 t e n d st ot a r g e tt or e g i o n sw i t hl o w e r
gene densities, particularly favoring regions with one to
two genes located within a 200 kb window on either
side of the insertion site (Figure 4B).
We next determined the targeting preferences of pig-
gyBac and Tol2 to different types of repeats in the
human genome. Up to 51.2% of Tol2 targets were found
within repeats, particularly LINEs (Figure 4C). The fre-
quency of targeting to repeats by piggyBac was 31.8%,
with a slight preference for SINEs. No piggyBac targets
were detected in Satellite and rDNA. Repetitive
sequences are stretches of DNA with similar sequences,
and are found in numerous locations in the genome. It
is possible that if one transposon displays a lower degree
of sequence constraints for targeting than the other one,
it may be able to target repeats more frequently than
the other one. Based on this assumption and the fact
that the sequences flanking the 3’ end are significantly
more important than that flanking the 5’ end for both
piggyBac and Tol2 target sites as determined by the
sequence logo analysis detailed later (Figure 5A), we
then applied sequence constraints to further address the
Table 1 The data sets of piggyBac and Tol2 genome-wide target profiling in HEK 293
Transposon # of individual
clones isolated
successful rate in
plasmid rescue
# of individual
plasmid rescued
# of targets with a
quality sequence
# of targets mapped
to the human genome*
Tol2 164 86% (142/164) 371 315 207
piggyBac 114 91% (104/114) 264 149 107
*: only the target sequences sharing ≥95% sequence identity with the corresponding human genome were selected
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Page 5 of 19targeting pattern of both transposons to different
repeats. In this analysis, we only counted the inserts
located at the site within and more than 100 bp
upstream to the 3’ end of targeted repeats (the lower
part in each bar in Figure 4C). By applying this
sequence constrain, the frequency of targeting repeats
decrease much more dramatically in piggyBac than in
Tol2 for the majority of repeat types (as compared the
lower part of each bar to the whole bar in Figure 4C)
suggesting that piggyBac may display a higher degree of
sequence constrains than Tol2 in selecting their target
sites.
Figure 3 Chromosome ideogram of target sites of piggyBac and Tol2 in HEK 293 The piggyBac and Tol2 targets are marked in red and
green triangles, respectively. The red and green stars label the site for piggyBac and Tol2 hotspots, respectively. Clusters (A-D) of Tol2 targets
are circled in purple.
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Page 6 of 19Figure 4 Preferential target sites of piggyBac and Tol2 transposons in HEK 293. A. The genome context of Tol2 and piggyBac target sites. *:
both transposons tend to insert near CpG islands more often than expected by chance (Tol2, P < 10
-9, piggyBac, P < 10
-11; see Methods). B. The
gene density around Tol2 and piggyBac target sites. C. Distributions of piggyBac and Tol2 target sequences in various types of repeats. Every bar
represents the percentage of target sites found in the type of repeats indicated. The bottom part of each bar represents the percentage of
targets located within at least 100 bp to the 3’ end of the repeats targeted.
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Page 7 of 19Figure 5 In-depth analyses of piggyBac and Tol2 target sequence preferences in HEK 293. A. The sequence logos of piggyBaca n dTol2
target sites. B. Two representative sequences flanking the sites repeatedly targeted by piggyBac. The TTAA tetranucleotide are underlined. C. A
sequence alignment of four sequences on chromosome 16 that share 100% sequence identity with the first 100 bp of the piggyBac target B89-4.
The residue that is different from the other three sequences at a given position is indicated in red. Dots represent all the primary sequences that
are identical in all four sequences. The numbers on the top indicate the relative position of residues. D. The sequence logo of 184 sequences
that share at less 97% sequence identity with the piggyBac target, B87-4. Note: The chromosomal sequence 5’ and 3’ to the target site are in
lower cases and upper cases, respectively. piggyBac transposon is inserted at the position between -1 and +1.
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To analyze the sequence preference for piggyBac and
Tol2 targeting, we generated sequence logos for both
transposon systems (Figure 5A). Consistent with pre-
vious reports, the characteristic TTAA tetranucleotide
was exclusively found at the piggyBac target sites.
Although no specific signature could be detected at
Tol2 target sites, a weak but significant preference was
observed in the first 10~11 bp 3’ flanking the target site.
Next, we searched for sites that are repeatedly targeted
by either piggyBac or Tol2. Five and six sequences tar-
geted repeatedly by piggyBac and Tol2, respectively,
were identified (Table 2). And four out of 207 (1.9%)
independent Tol2 t a r g e t i n ge v e n t so c c u r r e da tt h es a m e
position located within the intron of signal-regulatory
protein delta (SIRPD).
T of u r t h e re x p l o r et h en a t u r eo ft a r g e ts i t es e l e c t i o n
by piggyBac and Tol2, we performed a series of in-depth
analyses on their target sequences. By conducting a Blat
search against the UCSC genome browser database
(assembly hg18) [37], we identified 16 piggyBac and 12
Tol2 targeting sequences which have at least the first
100 bp nucleotides 3’ to the target site share more than
97% sequence identity with other sequences in the gen-
ome (Table 3). Surprisingly, 11 of the 12 Tol2 targets
were located within repeats, but none of the 16 piggyBac
targets was (Table 3). Again this observation may reflect
ah i g h e rd e g r e eo fs e q u e n c ec o n s t r a i n si nt a r g e ts i t e
selection for piggyBac than for Tol2. Further analyses
are required to reveal the nature of this discrepancy.
To study the nature of piggyBac target specificity, we
next examined the neighboring sequences around five
piggyBac hotspots. We observed that several TTAA tet-
ranucleotides are located within a 100 bp interval of two
piggyBac hotspots. The target sequences in B102-2 and
B38-4 are identical and contain three TTAA tetranu-
cleotides within a 100 bp interval upstream of the actual
piggyBac TTAA target (Figure 5B). Similarly, the
sequence of another piggyBac hotspot (as in B92-1 and
B75-4), contains three TTAA tetranucleotides within
the 100 bp interval downstream of the genuine TTAA
piggyBac target site. A Blat search has identified another
sequence which is located 3.3 Mb away and shares
99.5% sequence identity with the target site of B92-1
and B75-4. As detailed in the lower sequence of Figure
5B, a G (in red) to A substitution is identified at +88 on
the other sequence where the piggyBac target site is
designated as 0.
The fact that piggyBac targeted repeatedly to the same
TTAA but not the adjacent TTAA tetranucleotides or
to the TTAA site on another highly identical sequence
nearby raise the possibility that the genuine TTAA pig-
gyBac targets may be determined by some intrinsic
sequence constraints flanking the target site. To further
address this possibility, we focused on two other piggy-
Bac target sequences, the B89-4 and B87-4 (Table 3). By
a Blat search, we identified four sequences on chromo-
some 16 that share 100% sequence identity with one of
the piggyBac hotspot as in B89-4 and B77-4 (Table 3).
We then performed a multiple sequence alignment on
Table 2 The piggyBac and Tol2 hotspots in the HEK 293 genome
Transposon Target ID Targeted sequence Times Position Gene
context
Targeted
Gene
Near gene
(distance
bp)
Far gene
(distance
bp)
piggyBac B87-5/B89-3 TTAAATAAAGATAATAATACTAACCATGGCA 2 3p14.3 INTRONIC FLNB
B89-4/B77-4 TTAAAGACCCTGTCTCTTAAAAAAAAAAAAA 2 16p11.2 3’UTR MLAS
B38-4/B102-2 TTAAATAAAAAAGAACAGATATTTGAAATTG 2 14q23.3 INTRONIC GPHN
B71-1/B109-3 TTAAATTCCAGGTTTCTCAAAGAAAGCTTGT 2 20p12.3 INTERGENIC BC043288
(219296)
BMP2
(347908)
B75-4/B92-1 TTAAAGAAACAAGTTAACACCGAAGCCAGAG 2 17q24.1 INTERGENIC FLJ32065
(2686)
LRRC37A3
(101620)
Tol2 T47-2/T48-3 TGTTCCGCTCCTGGTGCGGGCCGAGACCCGG 2 1q21.2 INTRONIC ZNF687
111-2/T119-1 TATGTGTAATAATGGAGGTATGTACAACAT 2 3p24.3 INTERGENIC SGOL1
(385347)
HPX-42
(834010)
T14-3/T17-1 AGAATAGGTATTTCTTTTTTTCTTCTTATC 2 5q33.2 INTERGENIC C5orf3
(87465)
GRIA1
(92385)
T2-1/T3-2 TCCACCACAGCATGAGTTAAACCAAAGTCT 2 7q11.23 INTERGENIC POMZP3
(2680)
hPMSR6
(350693)
T1-3/T4-1 CCTGCCCAGCTCGTAAAAGGATGCTCACCT 2 8q22.3 INTERGENIC GRHL2 (694) NACAP1
(122197)
TB7-3/T113-1/
T115-4/T120-2
AATTTATCCATTTCTTCTAGATTTTCTAGT 2 20p13 INTRONIC SIRPD
Meir et al. BMC Biotechnology 2011, 11:28
http://www.biomedcentral.com/1472-6750/11/28
Page 9 of 19Table 3 The piggyBac and Tol2 targets located within the repetitive sequences of the HEK 293 genome
Transposon Representative
targets
Sequence (+1 ~ +30) Position Sequence identity Types of
repeats
Times
targeted
100% 99.9%
~97.0%
Total
piggyBac B89-4 TTAAAGACCCTGTCTCTTAAAAAAAAAAAA chr16
(30140496)
404 N F 2
B87-4 TTAAGAATGTTGAATATTGGCCCCCACTCT chr3
(55059477)
1 510 511 NF 1
B75-4 TTAAAGAAACAAGTTAACACCGAAGCCAGA chr17
(60391785)
112 N F 2
B85-4 TTAAAAAAGGCATTATTTTCGCAGCTATCT chr6
(125167100)
022 N F 1
B42-3 TTAATTTACTTAAGATAATGGCCTCCACAC chr22
(15414966)
538 N F 1
B100-1 TTAAGAAAGGAGTTGAATTAAGCTCAGGTT chr1
(120900969)
022 N F 1
B90-1 TTAATATCCCACCTTTGCACAGTAGACAAT chr3
(137392502)
202 N F 1
B92-2 TTAAACACACACTTAGAGGGAAATAATTCAT chr18
(11877795)
022 N F 1
B82-3 TAAAGAATATAAGGCCAAGCACAGTGGCT chr11
(27402368)
112 N F 1
B89-3 TTAAATAAAGATAATAATACTAACCATGGC chr3
(57972969)
112 N F 1
B92-1 TTAAAGAAACAAGTTAACACCGAAGCCAGA chr17
(60391785)
224 N F 1
B77-4 TTAAAGACCCTGTCTCTTAAAAAAAAAAAA chr16
(29401156)
044 N F 1
B79-2 TTAAGGGGGGAAAACAGTTCAGGGCCAACA chr14
(55711916)
112 N F 1
B84-1 TTAATGTTAAATTACAAACACTGTTTTATC chr18
(29434150)
022 N F 1
B85-1 TTAAGCACAGTATCAGTGATAAAAATAGCT chr1
(201276407)
112 N F 1
B82-1 TTAAGCTGAATCTGTTTTTCCCAGTGCCCC chr2
(231461932)
022 N F 1
Tol2 T111-3 TTTAAGAATGTTGAGTATTGGCCCCCACTC chr8
(9712455)
1 8 9 LINE 1
T147-1 ATCCTGAGCAGCCGAATCTGCAATCATCTT chr7
(154665283)
1 1 2 LTR 1
T3-2 TCCACCACAGCATGAGTTAAACCAAAGTCT chr7
(76097237)
2 0 2 LINE 1
T88-3 GTCTGTACTGCTGCAAAGCTTCACAGACAG chr10
(98485313)
123 N F 1
T115-4 AATTTATCCATTTCTTCTAGATTTTCTAGT chr20
(1472025)
0 3 3 LINE 4
T103-2 GGCGCCCGCCACTACGCCTGGCTAATTTTT chr21
(13847935)
1 3 4 SINE 1
T162-3 CCAGAGACCTTTGTTCACTTGTTTATCTGC chr20
(33206406)
202 ND >
202
Low_complexity 1
T157-1 CTCGTACGTAAGTTTTAGTGTGAACATATA chr4
(48956277)
4 3 7 LINE 1
T157-2 GTTAACAGTGACCTATTTGGGAGAAGGGGA chr7
(66290199)
1 1 2 LINE 1
T107-2 AATATATGAGTAGCTAAACAACTCTATAAG chr2
(97613844)
1 1 2 LINE 1
T104-1 GAACACATGGACACAGGAAGGGGAACATCA chr3
(134171282)
1 52 53 LINE 1
T25-3 ACCCCATCTCTACTAAAAATACAAAAAATT chr6
(166733349)
1 1 2 SINE 1
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these four sequences with a 200-bp interval on either
side of the TTAA target site is almost identical, both
B89-4 and B77-4 target to the same TTAA tetranucleo-
tide on the top but not the other three similar
sequences in Figure 5C. Another example, B87-4, was
found to share at least 97% sequence identity with 510
sequences elsewhere in the human genome, yet none of
these highly similar sequences were targeted by piggyBac
(Table 3). To gain further insight into the nature of pig-
gyBac target selection, we retrieved the top 184
sequences that share 99% sequence identity with the
first 100 bp of the B87-4 target. As revealed by the
sequence logo analysis, the primary sequence of these
184 sequences is highly conserved (Figure 5D). By desig-
nating the first T of TTAA as +1, the conserved A at
-51 and C at +99 are changed to C and T, respectively,
in the B87-4 target. Collectively, these observations
strongly suggest that piggyBac does not target arbitrarily
to any TTAA tetranucleotide in the human genome but
rather to the TTAA sites in a specific sequence context.
The activity of genes nearby the piggyBac and Tol2
hotspots
Genome-wide targeting analyses of retroviruses have
revealed their biased nature in preferentially targeting to
active regions of the host chromatin. To address
whether gene activity had an influence on target prefer-
ences of piggyBac and Tol2, we performed quantitative
RT-PCR (Q-RT-PCR) analyses, focusing mainly on
genes located within or within a 10 kb interval from
either Tol2 or piggyBac hotspots. The house keeping
gene GAPDH and three neural genes with a broad
range of expression levels in HEK 293 [38] were selected
to serve as references for Q-RT-PCR analyses. It is
impossible to assess the relative abundance of difference
genes by directly comparing the Q-RT-PCR signal
between various primer pairs. Hence, we designed the
primer pair within the same exon for each gene. The
expression level for each gene was then evaluated by the
ratio of the relative copy number derived from Q-RT-
PCR and that derived from quantitative PCR (Q-PCR)
by using the same primer pair on mRNA and the geno-
mic DNA of HEK 293, respectively. Most of the genes
tested were either not expressed or expressed at a much
lower level as compared to GADPH (Figure 6). Notably,
SIRPD, the gene containing the most frequently targeted
Tol2 hotspots was barely expressed in HEK 293 (Figure
6). Hence, it is highly likely that gene activity has no
influence on the hotspot selection of piggyBac and Tol2.
Indeed we have recently identified a piggyBac hotspot
located at a gene that is silenced in HEK 293 (Meir et.
al., unpublished observation).
Risk assessment of targeting within or near cancer-
related genes by piggyBac and Tol2
Random insertion mutagenesis is a real threat to gene
therapy [39]. The mutagenic potential caused by random
insertions of any transposon remains the greatest con-
cern for their advancement to clinical applications. In
this regard, we assessed the risk of Tol2 and piggyBac
for their potential of inducing oncogenesis by counting
the number of piggyBac or Tol2 targets located either
directly within or within a defined distance of a cancer-
related gene. The frequency of targeting to sites within
either a 400-kb or 1000-kb distance from cancer-related
genes was significantly higher in piggyBac than in Tol2
(Figure 7). However, the frequency of targeting within a
cancer-related gene was higher in Tol2 than in piggyBac
(Figure 7). Cancer related genes targeted by Tol2 or pig-
gyBac are listed in Table 4. Notably, piggyBac targeted
twice to the same site within one particular cancer-
related gene, gephyrin (GPHN), raising a great concern
for its safe use in gene therapy [40-42].
Discussion
The longer the foreign sequences introduced into the
host genome, the greater the probability of evoking
adverse consequences, such as transgene silencing and
dysregulation of the endogenous genes nearby. Hence,
for both basic research and clinical applications, a trans-
poson system with smallest terminal repeats for genetic
manipulations is desired. By removing most of the non-
functional sequences of piggyBac and Tol2 TRDs, we
observed a 1.5- and 3.3-fold increase in transposition
activity for piggyBac and Tol2, respectively. The increase
in transposition activity for both piggyBac and Tol2 is
unlikely to be due to their reduction in size, since the
piggyBac element in the pXLBacII-cassette and the Tol2
element in the Tol2ends-cassette are both within their
maximal cargo capacity of 9.1 Kb and 10 Kb, respec-
tively [14,22]. In general, the transposition activity of a
transposon negatively correlates with the fitness of the
host. Although in most cases the activity of transposons
in the host is abolished due to mutations and deletions,
some transposons are intact but are completely silenced
epigenetically by host defense mechanisms [43]. For
example, RNAi is the mechanism for silencing the Tc1
DNA transposon in the germ line of Caenorhabditis ele-
gans [44]. Unlike pXL-BacII-cassette only consisting of
245 bp-left and 313 bp-right TRD, the Tol2end-cassette
preserves most of the non-coding cis sequences of the
wild-type Tol2 transposon. These “non-essential
sequences” may be susceptible to epigenetic silencing
and in turn attenuate their transposition activity. This
possibility may explain why extra cis sequences in
Tol2ends-cassette has a greater impact in deregulating
Meir et al. BMC Biotechnology 2011, 11:28
http://www.biomedcentral.com/1472-6750/11/28
Page 11 of 19transposition activity than that of pXLBacII-cassette.
This observation further implicates the possible interac-
tion between epigenetic silencing factors and the cis
sequence of wild-type transposons, and for Tol2 in par-
ticular. Studies are now underway to address this
possibility.
Unlike our findings that pPB-cassette3short with short
TRDs at the ends results in a higher activity than its
long counterpart in HEK 293, attempts to transform D.
melanogaster with p(PZ)-Bac-EYFP consisting of 35-bp
3’TRD and 63-bp 5’TRD yielded transformation fre-
quencies far less than full-length piggyBac constructs
(reduced from 15% to 0.6%) [29]. This discrepancy may
simply reflect the differences in the components and/or
the mechanism involved in transposition between mam-
malian and insect cells. It is also possible that the extra
5 and 4 nucleotides included in our 3’-a n d5 ’-TRD,
respectively, are crucial for an effective transposition.
Figure 6 The activity of genes which are close to or located at the site repeatedly targeted by Tol2 or piggyBac. The upper panel is a
histogram showing the ratio of gene expression level between the housekeeping gene, GAPDH and the gene of interest that is either
repeatedly targeted by piggyBac or Tol2, or is located within a 10-kb interval of piggyBac or Tol2 hotspots as measured by Q-RT-PCR. A set of
neural genes (MK-1, NRGN, and SYGR4) with a high level to no expression in HEK 293 cells is also served as references. The lower panel is a
DNA-agarose gel image of a representative Q-RT-PCR reaction showing the PCR products at the end of the 30
th cycle. Genes targeted repeatedly
by piggyBac: FLNB; GPHN; and MLAS. Genes near the piggyBac hotspot: FLJ32065. Genes targeted repeatedly by Tol2: SIRPD and ZNF687. Genes
near the Tol2 hotspot: POMZP and GRHL2.
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Page 12 of 19Figure 7 A risk evaluation of piggyBac and Tol2 for targeting to the region located within or near cancer related genes in a genome-
wide scale. The histogram shows the percentage of piggyBac or Tol2 targets located within or within a defined distance away from cancer-
related genes.
Table 4 A list of cancer-related genes targeted by iggyback or Tol2
Transposon Target
ID
Sequence Targeted
Cancer Gene
Annotation
piggyBac B102-2 TTAAATAAAAAAGAACAGATATTTGAAATTGGCTGTTG GPHN gephyrin
B107-3 TTAATGATTCTTTCCATTTCTTTTATTCTTTTCCTAGC HHEX hematopoietically expressed homeobox
B27-3 TTAATAGAAAGGAAGGGACCATGTTTAACATAAATGCT POU6F2 POU class 6 homeobox 2
B38-4 TTAAATAAAAAAGAACAGATATTTGAAATTGGCTGTTG GPHN gephyrin
B63-1 TTAAGTTTTCAGTGGCTGAAAGTTGGCAGTCTGAAAAA ARF4 ADP-ribosylation factor 4
B81-1 TTAAGTGCTTTTGGCTGTTTTCCCAAACATCCAGACAT SMAD5 SMAD family member 5
Tol2 T12-2 GGTAGGAGTTATCTGAGTCAGGCCTGCCCTTGGCTTGG SPECC1 cytospin B
T121-1 CTCCTGGGTGACCCTCGCCTGAGCCTCCTGGCCCTTCC RAB40B RAB40B, member RAS oncogene family
T102-4 GACACAAACACACACATGCTATACCTTTGTATTACACT TCF4 transcription factor 4
T124-4 GCGGCTGTCCTCCAGCAACAGGTGCACATTCCCGGGCT TNK1 tyrosine kinase, non-receptor
T130-2 CAAATAAATGAATGTTATGAATTTTTGAGGGTAGGAAA SEMA3C sema domain, immunoglobulin domain (Ig),
(semaphorin) 3C precursor
T137-3 AAAGAGAGGCCCAATCCTGTGGAGTGAGTCACTGGGGG ALPL alkaline phosphatase, liver/bone/kidney
T137-4 ATTTTCTGTCTGCTCTTTGGTCACTTCCCATTCTTTTT PARD3 par-3 partitioning defective 3 homolog (C.
elegans)
T157-4 TTTATTTGTCCTGCACTTATGAAGCATAGTTTGGCAGG PGR progesterone receptor
T165-1 GAAACCGGCGAAAAGGTTAGCTGTCGCTGGCTAGTATT RASSF3 Ras association (RalGDS/AF-6) domain family
member 3
T22-1 TTCCTAAGCTACAATAAACCACATATGAAAAACTAAAG HD huntingtin
T26-1 AGCCTGAGTAAAATAGTGAGACTCTGTTTCTGCAAAAC LRP1B low density lipoprotein-related protein 1B
T43-3 TCTGGAAGGTGAGGCAGACGTGCCCACCGCCTCCATGC HLXB9 motor neuron and pancreas homeobox 1
T91-4 TTCAGGGGGTGTGTTGGAGGGGAATCGCCGGCCTGCCT IHH Indian hedgehog homolog (Drosophila)
TB7-5 AATTTATCCATTTCTTCTAGATTTTCTAGTTTATTCGC FKBP1A FK506 binding protein 1A, 12kDa
TB70-1 GTGCACACACTCACTCTCTCTTTCTCCTTCAGATAATA FOXP1 forkhead box P1
TB77-2 CCCCTCACCCTCGGACCCTTCACCGCGACCCCCGCGCC RANBP9 RAN binding protein 9
TB81-1 TGCAGTACAGTGCGGGGGGAAAAAAACAACAGCAAAAG EGF epidermal growth factor (beta-urogastrone)
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terminal sequences (referred as micro-PB hereafter) is
that most of the activator sequences (as underlined in
Figure 1A) identified previously in D. melanogaster [45]
are excluded. In this respect, the micro-PB may poten-
tially be a safer cis-piggyBac element as a mammalian
genetic tool as compared to the minimal piggyBac cis-
sequence identified previously. Studies are now under-
way to address whether micro-PB exhibits any enhancer
or silencer activity.
Genome-wide targeting profiles of piggyBac and Tol2
in the human genome have been previously reported
[31-34]. All of these analyses utilized chromosomal tar-
get sequences that were retrieved either by plasmid res-
cue from a heterogenous population of targeted cells or
by PCR-based strategies using a limited amount of
genomic DNA isolated from individual targeted clones
grown on 96-well plates. Several factors may introduce
strong biases into the data sets obtained in these studies
including (1) differences in proliferation rates of the
individual targeted cells, (2) intrinsic difficulties in
retrieving certain targeting sequences, and (3) biases in
obtaining PCR products from certain templates but not
from the others. Hence, to fully evaluate the pros and
cons of piggyBac and Tol2 for gene discovery and gene
therapy, a direct comparison of their genome-wide tar-
geting profile based on reliable data sets obtained within
the same experimental setting was needed. To achieve
this goal, we utilized a labor intensive strategy involving
isolating, expending, and performing plasmid rescue to
retrieve chromosomal targeting sequences for each indi-
vidual HEK 293 clone targeted. Based on the following
observations, we believe the data sets established in this
study provides reliable insights into the targeting profiles
of piggyBac and Tol2. First, we successfully rescued plas-
mids from 87% and 91% of piggyBac and Tol2 targeted
clones, and the majority of clones that were not rescued
were due to a lack of sufficient genome DNA for per-
forming plasmid rescue. Second, several copies of an
identical plasmid were often obtained in the same tar-
geted clones, suggesting that most, if not all, inserts in
the same clones were successfully recovered. Third, for
each individual clone targeted, we normally obtained 1-
4 different inserts, consistent with a recent report that
t h ec o p yn u m b e ro fTol2 and piggyBac in HeLa cells
ranges between 1-3 and 1-4, respectively [34]. Identify-
ing targeted sites in individual clones has led to the
identification of piggyBac and Tol2 hotspots and allowed
us to perform a detailed and unbiased analysis on target
site preferences for both transposon systems.
All piggyBac and Tol2 hotspots identified in this study
are likely to be bona fide given the following reasons.
First, the protocol (as detailed in the methodology sec-
tion) used to isolate individual targeted clones is
intentionally designed to avoid cross-contamination
between individual drug-resistant colonies. Second, all
of the target sequences in this study were retrieved
using plasmid rescue rather than a PCR-based strategy.
A small amount of contaminating genomic DNA, if any,
is not sufficient for a successful plasmid rescue. Third,
the four Tol2 targets mapped to the hotspot located in
the SIRPD locus were derived from two separate experi-
ments suggesting the occurrence of independent target-
i n ge v e n t sa tt h i sp a r t i c u l a rs i t ei nt h eH E K2 9 3
genome. Finally, all of the piggyBac and Tol2 clones
with a hotspot targeted contain additional integrations
mapped to distinct chromosomal locations (data not
shown), indicating all of these targeted clones were
indeed independent. Our analyses of Tol2 have revealed
a distinct global targeting distribution among 23 human
chromosomes in HEK 293, which stands in sharp con-
trast to the reported Tol2 distribution in HeLa cells
(compare Figure 4 with the Figure 6A in reference 34).
Distinct Tol2 genome-wide targeting profiles in HEK
293 and HeLa cells seem to reflect their difference in
frequency of targeting to different genomic contexts. For
instance, our analyses revealed 23.5% and 15.4% of Tol2
intronic and exonic targeting frequency in HEK 293,
respectively (Figure 5A), while the reported intronic and
exonic targeting rate of Tol2 in HeLa cells are 45.1%
and 3.5%, respectively (Table 2 in reference 34). Discre-
pancies in the frequency of Tol2 targeting to various
repeat types between our study and others were also
detected. Two factors may account for the observed dis-
crepancies: namely (1) differences in strategies, and (2)
differences in Tol2 targeting preferences in HEK 293
and HeLa cells. The former factor should not substan-
tially contribute to the great difference in targeting pre-
ferences seen in the two separate studies, since even if
one approach is less biased than the other, a certain
degree of overlapping in Tol2 target distributions should
still be detected in both human cell types. However, this
is not the case. Hence, the non-overlapping Tol2 target
profiles are likely due to differences in cell types. As for
piggyBac, although its intragenic target rate in this study
(51.6% in HEK 293) and in other studies (51.9% in pri-
mary T cells) is similar, we observed a much higher fre-
quency of piggyBac targeting to untranslated regions in
HEK 293 (15.8% total) than what was observed in pri-
mary T cells (1.7% total) (compare Figure 5A with data
reported in reference 35). Additionally, we fail to detect
any piggyBac targets that are found both in HEK293
(this study) and in human T cells [35]. Unlike the data
set established in this study, the genome-wide piggyBac
targets in primary T-cells were obtained from a hetero-
genous population of piggyBac targeted clones [35].
Consequently, the data set obtained from primary T-
cells is inevitably biased to the target sites that are easily
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significantly to the sharp contrast in the targeting pro-
files of piggyBac observed in the two different cell types.
However, our data set revealed five piggyBac hotspots in
HEK 293 and yet no target in our data set is found in
that of primary T cells, suggesting cell type differences
may still be the major contributing factors when
explaining these observed differences. Furthermore,
these differences were likely to be amplified by the fact
that unlike T-primary cells which contain normal 46
chromosomes, HEK 293 is a transformed cell line with
an aberrant karyotype of 64 chromosomes as character-
ized originally. Collectively, comparisons of our data
with that of others highlights the necessity for (1)
obtaining a reliable data set for genome-wide target ana-
lyses (preferably by retrieving all target sequences for
each individual targeted clone) and (2) re-evaluating the
genome-wide target profile of transposons (at least pig-
gyBac and Tol2) in the specific stem cell type of thera-
peutic interest before advancing them to clinical uses.
The reliable data sets obtained in this study allow us
to perform in-depth sequence analyses of their targets
without ambiguity. The sequence logo of Tol2 detected
subtle but significant information present within the
first 11 base pairs on the 3’ end of Tol2 target sites.
Furthermore, as indicated in Table 3 despite the fact
that the target sequence of the most frequently targeted
Tol2 hotspot (4 out of 207) is actually located within
LINEs and shares more than 97% sequence identity with
two other sequencesi nt h eg e n o m e ,Tol2 only targeted
to this particular site but not to other similar sequences.
Collectively, these observations strongly suggest even
though no distinct features of Tol2 target sequences can
be readily identified, Tol2, like piggyBac, also targets in a
selective manner in the host genome. The in-depth
sequence analyses also revealed the following important
features of piggyBac targeting preference: (1) TTAA
sites in a particular sequence context are targeted by
piggyBac, as opposed to arbitrary TTAA sites, (2) there
is no direct correlation between piggyBac hotspots (and
Tol2 hotspots as well) and the activity of genes either
contained within or near the hotspots, and (3) at least
the first 100 nucleotides on either side of piggyBac tar-
get site seem to be important for piggyBac target selec-
tion, and a subtle change in the primary sequence
within this 200 bp interval may result in losing its
potential for piggyBac targeting. These insights will pro-
vide a solid knowledge basis for engineering piggyBac
transposase to achieve site-specific therapeutic gene
targeting.
Powerful genetic tools enabling the probing of func-
tions of both coding and non-coding genome sequences
are urgently needed to facilitate the progress in deter-
mining the genetic factors that contribute to our
uniqueness as human beings in a post-genomic era. The
fact that piggyBac favorably targets intragenic chromoso-
mal regions makes it a great tool for uncovering the
functions of protein coding genes. Transposable ele-
ments are often considered “junk” DNA in the human
genome. An increasing body of evidence, however, sug-
gests that a fraction of these repetitive sequences are
active and play import roles in epigenetic gene regula-
tion [43,44,46,47]. The preference of Tol2 to target
genomic repeats makes it an ideal tool for revealing new
functions of transposable elements residing in our gen-
ome. Collectively, the non-overlapping genome-wide tar-
get profiles of piggyBac and Tol2 potentially makes them
complementary research tools for studying the human
genome.
Genotoxicity caused by a single integration event
mediated by the retrovirus-based vector has resulted in
the development of T-cell leukemia in 5 of 20 patients
treated for SCID with one death reported [39]. Hence,
no wild type DNA transposon is considered safe for
gene therapy since they all introduce transgenes into a
host genome in a random fashion. Indeed, our genome-
wide target profiling of piggyBac in HEK 293 revealed a
piggyBac hotspot located within the coding region of
gephyrin, a scaffold protein implicated in colon cancer
and adult T-cell leukemia [40-42]. Most active mamma-
lian genome manipulating enzymes, including viral inte-
grases and DNA transposase, must therefore be
molecularly modified to achieve the ultimate goal in
gene therapy: targeting the therapeutic gene into a pre-
determined genomic site where the therapeutic gene can
be stably and faithfully expressed without disturbing the
global gene expression profile. Put into perspective, pig-
gyBac is by far the most promising vector system for
gene therapy, as piggyBac transposase is the only one
capable of being molecularly modified without substan-
tially losing activity (reference 15 and this study).
Conclusions
The transposon-based tool box for mammalian genomic
manipulations is expanding. Here, we engaged in a side-
by-side comparison of two highly effective mammalian
active transposons, piggyBac and Tol2,t oe v a l u a t et h e i r
pros and cons for gene discovery and gene therapy. We
report the identification of the shortest piggyBac TRDs,
micro-PB, which have a higher transposition efficiency
in HEK 293 than that of the previously reported piggy-
Bac minimal terminal repeat domains, mini-piggyBac.
Our genome-wide target profiling reveals that piggyBac
and Tol2 display complementary targeting preferences,
making them suitable tools for uncovering the functions
of protein-coding genes and transposable elements,
respectively, in the human genome. Our results suggest
that piggyBac is the most promising DNA transposon
Meir et al. BMC Biotechnology 2011, 11:28
http://www.biomedcentral.com/1472-6750/11/28
Page 15 of 19for gene therapy because its transposase is likely the
most amenable mammalian genetic modifier for being
molecularly engineered to achieve site-specific therapeu-
tic gene targeting. Our in-depth sequence analyses of
piggyBac targets revealed that the sequence context near
and within a considerable distance from the TTAA pig-
gyBac target site is highly important in site selection.
Based on this observation, it is clear that in order to
advance piggyBac for a clinical use in gene therapy, a
safe and favorable site for piggyBac targeting in the gen-
ome of the appropriate therapeutic stem cell should first
be identified, followed by the engineering of piggyBac
transposase to achieve site-specific gene targeting.
Methods
Transposon constructs
The plasmid construction described in this study followed
the protocol of Molecular Cloning, 3
rd edition, CSHL [48].
The sequences of all constructs involving PCR-based clon-
ing were confirmed by DNA sequencing. The process of
each construction is described briefly as follows:
(1) pPB-cassette3short
The short piggyBac TRDs (i.e. 746~808 3’ LTR and
1426~1460 5’ LTR as in pXL-BacII [29,30]) were
obtained from the PCR mixture consisting of the follow-
ing four pairs of primers; pB-11-KpnI (atcgggtacct-
taaccctagaaagataatcatattg), pB-5-forward (ggtaccCC-
CTAGAAAGATAATCATATTGTGACGTACGTTAA
AGATAATCATGCGTAAAATTGACGCATGctcgag),
pB-6-reverse (gagctcCCCTAGAAAGATAGTCTGCG-
TAAAATTGACGCATGccaccgcggtggatttaa atctcgag-
catgcgtca), and pB-12-SacI (cgatgagctcttaaccctag-
aaagatagtctgcg). The resulted amplicon containing both
67 bp 5’ and 40 bp 3’ TRD with SwaI and Xho I restric-
tion sites in between was cloned into pBS-SKII through
Kpn I and Sac I restriction sites to obtain the pPBen-
dAATT. The same cassette (containing the hygromycin
resistant gene driven by SV40, the replication origin,
ColE1, and the kanamycin resistant gene) as in pXLBa-
cII-cassette [15] was inserted between short piggyBac
TRDs in pPBendAATT through the blunt-ended Xho I
site to make the intermediate construct, pPBcassette3.
To generate the pPB-cassette3short, pPBcassette3 was
digested with Acc65 I and Afl III to remove the ampicil-
lin resistant gene and the f1 replication origin. The
remaining DNA fragment was blunt-ended followed by
self-ligation to generate the final construct, pPB-
cassette3short.
(2) pTol2mini-cassette
To construct the Tol2 donor with short TRDs, two
separated PCR products were generated by two sets of
primers, Tolshort-1 (atcgggtaccatttaaatCAGAGGTG-
TAAAGTACTTG)/Tolshort-2 (tatcaagcttagatcta-
gAAGTGATCTCCAAAAAATAAG) and Tolshort-3
(ctaagcttgatatcaacggatccAATACTCAAGTACAATTT-
TAATGG)/Tolshort-4 (cgatgagctcatttaaatCAGAGGTG-
TAAAAAGTACTC), respectively using the Tol2end-
cassette [15] as a template. Next, these two PCR pro-
ducts were served as templates to produce the third
PCR product using the Tolshort-1 and Tolshort-4. The
third PCR product was cloned into the Kpn I and Sac I
site of pBS-SK II vector to generate the miniTol2-end.
The same cassette as described in section (1) above was
then inserted into the EcoR V site of miniTol2end to
generate pTol2mini-cassette.
(3) pPRIG-piggyBac
To generate pPRIG-piggyBac, the coding sequence of
the piggyBac transposase was PCR amplified from
pcDNA3.1Δneo-piggyBac [15] using primer piggyBac-10
(ATCGGAATTCACCATGGGTAGTTCTTTAGACG)
and primer piggyBac-11 (AAGGCACAGTCGAG
GCTG). The PCR product was cloned into the EcoR I
and Not I site of the pPRIG vector.
(4) pPRIG-Tol2
T h ec o d i n gs e q u e n c eo ft h eTol2 transposase was
obtained from the Xba I/BamHI restriction fragment of
pcDNA3.1Δneo-Tol2 [15] and then inserted into the Stu
I and BamHI sites of pPRIG vector.
(5) pCMV-Myc-piggyBac
T h es a m ef r a g m e n tc o n t a i n i n gt h eO R Fo fpiggyBac
transposase as described in section (3) above was cloned
into the pCMV-myc vector (Clontech, Inc) to generate
pCMV-Myc-piggyBac.
(6) pPRIG-HA-Tol2
A pair of complementary oligos containing the sequence
of the HA tag was synthesized, annealed and inserted
into the BamHI site of pPRIG-Tol2 vector to generate
pPRIG-HA-Tol2 which expresses a N-terminal HA
tagged Tol2 transposase. The clones with a correct orien-
tation were obtained and verified by DNA sequencing.
(7) pPRIG-Tol2-HA
pPRIG-Tol2-HA expressing the C-terminal HA tagged
Tol2 transposase was constructed by swapping the
restriction fragment of XcmI and SphI of pCR4-TOPO-
Tol2HAc (the detailed procedure regarding the con-
struction of this plasmid is upon requested) with those
in pPRIG-Tol2.
Cell culture and transposition assay
HEK 293 cells were maintained in MEMa medium
(HyClone) supplemented with 10% FBS (HyClone), 100
units/ml penicillin, and 100 μg/mL streptomycin. The
details for the transposition assays were described pre-
viously [32].
Activity assay of the piggyBac transposase
A similar procedure as detailed previously [32] was used
to co-transfect 100 ng of piggyBac donor, with various
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ranging from 0 - 300 ng into 1.2 × 10
5 of HEK 293
cells. pcNDA3.1ΔNEO, an empty vector used in our
previous study (Wu et.al 2006), was used to top the
total amount of DNA transfected to 400 ng. Each trans-
fection condition was done in triplicate. Twenty four
hours after transfection, one fifth of transfected cells
were subjected to transposition assay. The remaining
transfected cells (4/5) in triplicate were pooled and grew
in a 35-mm plate for another twenty four hours before
being subjected to Western blotting. For Western blot-
ting, total proteins were extracted using RIPA buffer (50
m MT r i s ,p H8 . 0 ,1 5 0m MN a C l ,1 %N o n i d e tP - 4 0 ,
0.1% SDS, 0.5% sodium deoxycholate, and 1:100 diluted
proteinase inhibitor cocktail) and quantified using the
Lowry assay (Biorad). Twenty μg of total proteins were
separated by SDS-PAGE on a 8% acrylamide gel. After
electrophoresis, the gel were transferred to PVDF mem-
branes (millipore). The membrane was then probed with
anti-Myc antibody at 1:1000 (Clontech) and anti-a actin
antibody (Calbiochem) at 1:10,000. After three washes, a
secondary antibody, peroxidase-conjugated goat anti
mouse IgG, was added. After incubation and three
washes, the secondary antibodies were subsequently
detected by ECL.
Retrieving chromosomal sequences flanking the
transposon targets by plasmid rescue
The same transfection procedure detailed previously was
used to transfect the piggyBac donor, pXLBacII-cassette,
and Tol2 donor, Tol2ends-cassette, along with their cor-
responding helper, pPRIG-piggyBac and pPRIG-Tol2,
respectively, into HEK 293 cells using Fugene HD
(Roche). The transposition efficiency for pXLBacII-cas-
sette and Tol2ends-cassette is around 1~2%. To avoid
the duplication of the same targeted cell, twenty four
hours after the addition of Fugene HD, transfected cells
were subjected to a series dilutions and then grown in
the hygromycin (100 μg/ml) containing culture medium
at a density (about 20 ~ 30 colonies per 100-mm plate
as estimated from 1~2% of transposition rate) enabling
for isolating individual colonies without cross-contami-
nation. Two weeks after selection, colonies which were
at a great distance away from adjacent colonies were
individually cloned and expanded until reaching conflu-
ence on 100-mm dishes. Genomic DNA of individual
clones was isolated and subjected to plasmid rescue.
Detailed procedures for plasmid rescue were described
previously [32]. Plasmids rescued from the same tar-
geted clone were digested with Hinf II (4-cutter restric-
tion enzyme). For each targeted clone, only plasmids
showing different Hinf II digestion patterns were sub-
jected to sequencing. Based on the Hinf II digestion pat-
tern, all of the colonies isolated displayed a distinct
repertoire of rescued plasmids indicating that each iso-
lated colony was indeed derived from different targeted
cells.
Q-PCR and Q-RT-PCR
HEK 293 cDNA was obtained using the FastLane Cell
cDNA kit (Qiagen). One point three μlo fc D N Aa n d
0.125 μg (predetermined by a series dilution of genomic
DNA) of HEK 293 genomic DNA were subjected to Q-
PCR using primers listed in 2. Q-RT-PCR was per-
formed using SYBR Green PCR Master Mix (Applied
Biosystems) in 20 μl of reaction on 7500 Fast Real-Time
PCR System (Applied Biosystems). The expression level
of individual transcripts was determined by dividing the
copy number of each cDNA with the copy number of
the corresponding gene using following formula: 2
(Ctge-
nomic DNA-CtcDNA). The relative expression level between
each gene and GAPDH was calculated by the ratio of
the gene expression level between the two.
Bioinformatic analyses
Target sites were identified in build hg18 of the human
genome using Blat [37], with a sequence identity cutoff
of 95%. Human genes were obtained from RefSeq [49],
and 2,075 cancer-related genes were taken from the Can-
cerGenes database [50]. Upon counting the number of
genes within n base intervals, all overlapping genes were
f i r s tm e r g e dt oa v o i do v e r - c o u n t i n g .C p Gi s l a n d sw e r e
taken from the UCSC Genome browser “CpG Island”
track, which identifies CpG islands based on the methods
of Gardiner-Garden and Frommer [51]. Repeat elements
predictions were obtained from RepeatMasker [52]. Only
insertions whose first 100 bases are contained within a
repeat element were considered to overlap a repeat ele-
ment. To estimate the significance of the tendency of
insertions to be located proximal to CpG islands, we
compared the number of insertions located within 2,000
bases of a CpG island to the number expected by chance.
The expected number was calculated for each transposon
type by picking N random regions in the genome of the
same size (in bases) as the given transposon, where N is
the total number of insertions for the given transposon.
This procedure was repeated 1,000 times, and the mean
and standard deviation of the number of random inser-
t i o n sp o i n t sw i t h i n2 , 0 0 0b a s e so faC p Gi s l a n da c r o s s
the 1,000 random trials were used to obtain a Z-score
(and associated P-value) for the actual number of inser-
tions located within 2,000 bases of a CpG island.
Additional material
Additional file 1: Table S1. Clusters of piggyBac and Tol2 target sites
located within a 10 kb interval in HEK 293. A table lists piggyBac and
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Page 17 of 19Tol2 targets that are clustered within a 10 Kb interval to the adjacent
targets
Additional file 2: Table S2. A list of primer pairs for Q-RT-PCR analyses.
This file contains sequence information for primers used for Quantitative-
PCR and Quantitative RT-PC analyses
Abbreviations
LINE: Long interspersed nuclear element; SINE: Short Interspersed nuclear
Element; TRD: Terminal repeat domain; TIR: terminal inverted repeat; PCR:
polymerase chain reaction; Q-RT-PCR: Quantitative reverse transcription PCR
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